Further, GLP-1RAs block the adhesion of monocytes to endothelium induced by oxidized LDL via extracellular signal-regulated kinase (ERK) 5-Kruppel-like factor (KLF)2 signaling pathway to prevent endothelial permeability [107, 108]
In fibroblast-like RA synoviocytes, the administration of lixisenatide resulted in a reduction in the inflammatory response.347 This was achieved by decreasing the expression of proinflammatory cytokines such as tumor necrosis factor (TNF), interleukin-6 (IL-6), and interleukin-8 (IL-8).15,351,352 Moreover, lixisenatide has been shown to inhibit matrix metalloproteinase (MMP) activity and effectively block various cell signaling pathways, including the JNK, activator protein-1, and NF-B pathways.353 These findings confirm that in the synovium, GLP-1R is expressed on two different cell types, macrophages and fibroblast-like synoviocytes, which are specialized cells distributed within the synovial intima and subintima, and these cell types play important roles in hyaluronic acid synthesis, metabolite processing, and clearance of matrix degradation fragments.354 GLP-1RAs and musculoskeletal healthGLP-1RAs and bone The quality of bone depends on bone metabolism, and the main factors affecting bone metabolism include osteoclasts, osteoblasts, and calcitonin.355,356,357 According to most related studies, osteoclasts and osteoblasts are indispensable for bone remodeling, and bone resorption and bone formation are mediated by osteoclasts and osteoblasts, respectively.358 GLP-1R is present in bone marrow stem cells (BMSCs),15,359 osteoblasts,15 osteocytes,360 and osteoclasts,361 and GLP-1RAs have the potential to impact these cells
Equilibrate TMB substrate to 37C before staining
Using scientifically substantiated ingredients and appropriate documentation can help support structure-function claims, but brands should separately substantiate any claim that an ingredient addresses an effect associated with GLP-1 medication use or rapid or significant weight loss
Such studies are small and insufficient, as yet, to convince the regulators to broaden the acceptable indications to include people with a pouch
